Coca-Cola and Other Dividend Kings That Have Raised Their Payouts for 60 Years or More ...

Johnson & Johnson (JNJ) closed the most recent trading day at $161.63, moving +0.06% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.15%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq increased by 0.09%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 4.17% over the past month. This has lagged the Medical sector's gain of 6.58% and outpaced the S&P 500's gain of 3. ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Key TakeawaysJohnson & Johnson said Monday that it bought Ambrx Biopharma for about $2 billion to boost its oncology portfolio.The $28-per-share all-cash offer is at a 105% premium to Ambrx's closing price on Friday.Ambrx's clinical and preclinical treatments use antibody drug coagulates to attack a variety of cancer cells.Ambrx shares more than doubled following the news, hitting an all-time high.Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would pu ...

ToplineJohnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm’s marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.The pharmaceutical firm faces thousands of lawsuits alleging its talcum powder poses cancer risks. Getty Images Key FactsThe tentative agreement will end an ongoing probe into Johnson & Johnson’s talcum-based baby powder and w ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

BlackJack3DStelara, Johnson & Johnson's (NYSE:JNJ) leading product, is nearing the end of its exclusivity outside the US by mid-2024 and in the US by early 2025. Stelara is a significant part of JNJ's sales and operating income, making up about 13% of total sales and 24% of operating income in 2023. This loss of exclusivity will likely slow down the growth of earnings per share (EPS) for JNJ, which is a shift from their previous aim of growing EPS faster than sales. Analysts currently predict declines o ...

Mario Tama Dear readers, Johnson & Johnson (NYSE:JNJ) is arguably one of the safest businesses in the world, as it is one of only two companies that have an AAA rating which is higher than the AA+ rating of the U.S. government. It is also a dividend king with a 60+ year history of dividend increases and a defensive stock which I believe is suitable for most portfolios. I argued in a recent article on Procter & Gamble (PG) why I like to allocate a portion of my capital to Staples. JNJ shares a lot of the sam ...

yorkfotoIntroduction "What's the Fed going to do?" may be the single most important question this year. If we were to ask the market, it would tell us that the Fed will cut rates six times this year. CME GroupWhile Fed Funds Futures, the tool used to arrive at this estimate, are highly volatile, I believe the fact that six cuts are now the consensus estimate worries me a bit. After all, if inflation remains elevated, the Fed will have to keep rates higher for longer, causing markets to price in the impa ...